SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pz who wrote (775)8/16/1999 9:04:00 PM
From: Mad2  Read Replies (2) of 5582
 
Dan and Howard
The following appeared in Gum's release
''We are pleased with our continued progress in increasing net sales
on a year-to-year basis. Sales of Zicam(TM) were as expected. As noted at the end of
the last reporting period, we anticipate that increasing sales of Zicam(TM) will start to be
reflected in the third quarter.''
Key statement is Zicam sales were as expected. Someone should ask GUMM mgmt what they expect in the 3rd and 4th qtr, given their smug confidence on "hitting the numbers" and given many a investor in GUMM is counting on Zicam to justify the stock price.
GUMM investors should ask mgmt to share their projections with them (revenue and operating profit) and lend objectivity to the share ownership issue, otherwise unrealstic expectations drive price and opportunistic "insiders" are the benificaries.
Best Regards,
Mad2
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News